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Suppression of apoptosis is one of the hallmarks of carcino-
genesis. Tumor cells endure apoptotic pressure by overex-
pressing several antiapoptotic proteins, and FLICE inhibitory
protein (FLIP) is one of the important antiapoptotic proteins
that have been shown to be overexpressed in various primary
tumor cells. FLIP has two death-effector domains in tandem,
mimicking the prodomain of procaspase-8. It is recruited to
Fadd in death-inducing signaling complex, thereby preventing
the activation of procaspase-8. To date, three isoforms of
human cytosolic FLIP (c-FLIP) and six viral homologs
(v-FLIP) have been identified. Recently, the crystal structure
of v-FLIP MC159 was determined for the first time as an
atomic-detail FLIP structure, which revealed that two death
effector domains are packed tightly against each other mainly
through conserved hydrophobic interactions. The overexpres-
sion of c-FLIP in tumor cells has been shown to be the
determinant of the tumor’s resistance to death ligands such as
FasL and TRAIL. It has also been shown that the down-
regulation of c-FLIP results in sensitizing resistant tumor cells.
Therefore, the agents directly targeting c-FLIP at mRNA and
protein levels are expected to be developed in near future and
tested for the potential as a new class of anti-cancer drugs.
Kew Words: FLICE inhibitory protein, death-inducing signaling
complex, Fas, apoptosis, cancer
APOPTOSIS AND CANCER
Apoptosis is a programmed way of cell death
which has been characterized by shrinking of
cells, condensation of nuclei, and internucleosomal
degradation of DNA.
1,2 Within 24 hours after this
program is switched on, the apoptotic cell divides
into small blobs and is finally engulfed by
neighboring cells.
3 Since Dr. Stanley Korsmeyer
had shown that apoptosis program is suppressed
in B-cell lymphoma and its suppression enhances
the development of B-cell lymphoma, thousands
of studies have been accumulated to support the
idea that the acquired resistance to apoptosis is a
hallmark of most or perhaps all types of cancer.
4
Moreover, a significant part of the benefits
achieved by chemotheraphy relies on the induc-
tion of apoptosis in tumor cells,
5 and cancers with
alterations in proteins involved in apoptosis
signaling are often resistant to chemotheraphy.
6
Therefore, drugs designed to restore the apoptosis
program might be effective against tumor cells.
For selectivity, such drugs might induce cell death
of only tumor cells because, unlike normal cells,
they are under apoptotic stress and highly depen-
dent on aberrations of the apoptosis signaling
pathways to stay alive.
6 For these reasons,
apoptosis has been a very attractive phenomenon
for the researchers who seek new strategies to
fight against cancer.
Antiapoptotic proteins overexpressed in tumor
cells have been recognized as targeting points
for anti-cancer therapeutic interventions, and
their inhibitors at the levels of mRNA and
protein have been developed, which are mostly
antisense oligonucleotides and small molecule
inhibitors.
6-8 Those drug candidate compounds
are now mostly in the preclinical and early clinical
stages. FLIP is an another important antiapoptotic
protein overexpressed in various types of tumor
cells,
9 but the agents directly targeting it have
not yet been reportedly developed.
8 In this
review, recent progress on FLIP research and its
potential as an anti-cancer therapeutic target will
be discussed.
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INITIATOR CASPASE ACTIVATION IN
INTRINSIC AND EXTRINSIC PATHWAYS
The central executioner of apoptosis is a set of
cysteine proteases called caspases that are initially
synthesized as inactive zymogens called pro-
caspases. Upon the induction of apoptosis,
procaspase is cleaved into p18 and p10 to form
the active enzyme, which is a heterotetramer
containing two p18/p10 heterodimers and two
active sites.
10 Based on their order of activation,
caspases are classified into two families: initiator
caspases and effector caspases.
11 Initiator caspases
(also known as apical caspases; caspase-8 & -9) are
activated through autocatalytic cleavage on their
own activation platform formed in response to
upstream death signals. For example, caspase-8 is
activated in death-inducing signaling complex
(DISC) whose major components are Fas and
Fadd.
12-14 In caspase-9, the proteolytic activation is
accomplished in apoptosome composed of Apaf-1
and cytochrom c (Fig. 1).
11 Effector caspases (also
known as executioner caspases) are proteolytically
activated by initiator caspases. Once activated,
effecter caspases (caspase-3 & -7) degrade more
than 280 cellular proteins identified so far and
consequently execute the cell death process.
15
Death signals to activate the initiator caspases
can occur internally from cytotoxic insults such as
DNA damage or can be given externally in a form
of cytokine collectively called as death ligands
including Fas ligand (FasL) and TRAIL.
7 In
intrinsic pathway, DNA damage leads to the
phosphorylation of p53, which then induces
transcriptional activation of proapoptotic proteins
such as Bax, Puma and Noxa.
16 These proteins
change the permeability of mytochondiral mem-
brane, which results in the release of several
proteins including cytochrome c. Cytochrome c in
cytosol interacts with Apaf-1 and they form a
heptameric complex called apoptosome where
procaspase-9 is activated (Fig. 1).
11 In extrinsic
pathway, binding of the trimeric death ligand to
the death receptor induces the oligomerization of
the death receptor which leads to the formation of
DISC where procaspase-8 is recruited and
activated.
12-14 Death receptors are a subfamily of
the TNF receptor superfamily, and eight human
death receptors have been identified; Fas (also
known as Apo-1 and CD95), TNF-R1, DR-3 (Apo-
3, TRAMP, WSL-1, LARD), TRAIL-R1 (DR-4),
TRAIL-R2 (DR-5), DR-6, EDA-R and NGF-R.
17 All
death receptors have a death domain in their
cytosolic part where the downstream signaling
protein binds. Fas has been the most studied
death receptor to date. Binding of FasL induces
the oligomerization of Fas, and Fas recruits its
downstream cytosolic adaptor protein Fadd,
which in turn recruits procaspase-8.
12-14 In addi-
tion to Fas, TRAIL-R1 and -R2 should be men-
tioned as members of special interests because
their common ligand TRAIL was shown to induce
apoptosis selectively in tumor cells but not in
normal cells, highlighting its potential therapeutic
Fig. 1. Apoptosis signaling and
the caspase activation.FLIP as an Anti-Cancer Therapeutic Target
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application in cancer treatment.
18,19
Protein-protein interactions in the activation of
initiator caspases are mediated by three similar
domains, which are death domain (DD), death-
effecter domain (DED), and caspase-recruiting
domain (CARD). In DISC for caspase-8 activation,
DD in the cytosolic part of Fas interacts with DD
of Fadd, and DED of Fadd in turn with DED of
procaspase-8. In case of caspase-9 activation,
Apaf-1 recruits procaspase-9 through CARD-
CARD interaction. These three domains comprise
the death domain superfamily, and they com-
monly adopt a simple globular fold of the charac-
teristic hexahelical bundle in a Greek key topology.
Even though these three domains are very similar
in structure, their interactions are highly specific
so that they interact only in a homotypic way (i.e.
DD-DD, DED-DED, and CARD-CARD) and there
is no established interaction across members at
least to date.
20 These homotypic interactions of
DD, DED and CARD play an essential role in
forming heteromultimeric platforms for the initia-
tor caspase activation, i.e. DISC and apoptosome,
as well as in recruiting the proenzyme of the
initiator caspases to those platforms.
FLIP AS AN INHIBITOR OF RECEPTOR-
MEDIATED APOPTOSIS
Procaspase-8 has two DEDs in the N-terminus
of the catalytic domain, and Fadd has one DED
in the N-terminus. In 1997, other DED-containing
proteins have been identified in several - γ
herpesviruses and the poxvirus MCV.
21-23 They
have been collectively called viral FLICE inhibi-
tory proteins (v-FLIP) because they show inhibitory
effects on apoptosis signaling of caspase-8 which
is also called FLICE. Soon after the identification
of v-FLIP, their human cellular homologs
(cellular-FLIP, c-FLIP) were also identified (Fig.
2).
24,25 Although 13 distinct splice variants of
c-FLIP mRNA have been described,
26 only three
have been detected at the protein level; c-FLIPL,
c-FLIPS, and c-FLIPR.
24-27 The long isoform c-FLIPL
has a domain structure similar to procaspase-8:
two DED’s in N-terminus and caspase-like
domain in C-terminus. However, its caspase-like
domain lacks the catalytic cysteine residue con-
served in caspases and consequently it is catalyti-
cally inactive. All three isoforms of c-FLIP as well
as v-FLIP have been reported to be recruited to
DISC through its tandem DEDs interacting with
DED of Fadd, and FLIP thereby excludes pro-
caspase-8 from DISC. This may be the common
mechanism of various FLIP’s to inhibit the caspase-
8 activation, although MC159 (v-FLIP from MCV)
seems to act in a slightly different way.
28
Although c-FLIPL has been described in most
reports as an inhibitor of caspase-8 activation in
DISC, some other studies show that c-FLIPL can
activate the caspase-8.
29-33 Recently, it has been
proposed that c-FLIPL can be either antiapoptotic
or proapoptotic depending on its expression
Fig. 2. Various FLIPs and procaspase-8.
Arrows denote the sites cleaved by
caspase-8 or procaspase-8. Shadow
region in the C-terminus of c-FLIPR is
its own unique 11-residue-long sequence
which is not observed in other two
isoforms, c-FLIPL and cFLIPS.Jin Kuk Yang
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level,
34 although all other FLIP’s have been reported
to be solely anti-apoptotic. At low expression
levels, which are probably found in most cells,
c-FLIPL enhances the caspase-8 activation. At
intermediate expression levels, found in some cell
types such as monocytes/macrophages and certain
tumors, c-FLIPL acts as an inhibitor of caspase-8
activation. At very high non-physiological concen-
trations achieved by transient overexpression,
c-FLIPL is cytotoxic by itself without the need for
stimulation of Fas.
34 Despite the dual role of c-FLIPL
in caspase-8 activation, it should be emphasized
that c-FLIPL acts as an antiapoptotic protein to
inhibit caspase-8 activation at least in the range of
physiological expression level in tumor cells.
NONAPOPTOTIC FUNCTIONS OF FLIP
In addition to its activity in apoptosis signaling
pathway, c-FLIPL has been reported to activate
NF- B pathway, especially in lymphocytes. κ
35-39
NF- B activation by c-FLIP κ L requires the cleav-
ages of c-FLIPL at Asp-376 by fully processed
mature caspase-8, i.e. p102-p182 heterotetramer,
and/or at Asp-196 by procaspase-8.
37,38 Intere-
stingly, mature caspase-8 and procaspase-8 showed
mutually exclusive proteolytic specificity on two
cleavage sites in c-FLIPL.
38 These cleavages generate
tandem-DED-containing N-terminal fragments of
the molecular weight around 43 kDa and 22 kDa
which are called p43-FLIP and p22-FLIP respec-
tively. It has been shown that p22-FLIP can also
be generated also from c-FLIPS.
38 Both the FLIP
N-terminal fragments activate NF- B signaling via κ
binding to the components of NF- B signaling κ
pathway; p43-FLIP binds to TRAF237 and p22-
FLIP directly binds to IKK complex.
38 Notably,
caspase-8 has also been reported to be essential
for NF- B activation in T, B and NK cells. κ
40,41
Involvement of c-FLIPL and caspase-8 in NF- B κ
activation may explain the dual role of c-FLIPL in
caspase-8 activation discussed in the previous
section.
42 NF- B activation by c-FLIP κ L and
caspase-8 has been shown to play an important
role in lymphocyte proliferation.
37,38 In addition to
NF- B signaling, c-FLIP κ L has also been shown to
activate Erk signaling pathway by binding to
Raf-1.
35,43
FLIP STRUCTURE IN ATOMIC DETAIL
The structure of a viral FLIP, MC159, has
recently been revealed by X-ray crystallography
for the first time as a FLIP structure (Fig. 3A).
28,44
It shows that DED1 significantly deviates from the
canonical death fold observed in Fadd DED
45 and
Fas DD.
46 MC159 DED1 lacks the helix 3, and
there is instead a short loop structure. The crystal
structure also revealed that two DEDs pack tightly
against each other through hydrophobic interac-
tion. The atomic-detail DED-DED interaction
mode observed in MC159, although intramole-
cular, vividly contrasts to the previously reported
intermolecular CARD-CARD interaction between
procaspase-9 and Apaf-1 (Fig. 3A and 3B).
47
Firstly, the CARD-CARD interface involves the
helix 2/3 face (Apaf-1) and the helix 1/4 face
(procaspase-9). In MC159 structure, however, the
helix 2/5 face of DED1 meets the helix 1/4 face
of DED2. Secondly, the interactions between two
CARDs are mainly electrostatic. In contrast, the
DED-DED interactions in MC159 are mainly
hydrophobic. Interestingly with regards to the
hydrophobic interface, the conserved hydrophobic
patch in DED1 is buried in the interface, and the
one in only DED2 is exposed. The hydrophobic
patch is conserved in all known DEDs and has
already been shown to be critical for the interac-
tion of Fadd with other DED proteins such as
procaspase-8.
45 Other important observation is
that the hydrophobic residues comprising this
intramolecular DED-DED interface are conserved
in other tandem-DED-containing proteins such as
procaspase-8, -10, c-FLIP, and other v-FLIP’s (Fig.
3C). It implies that two DEDs in those proteins
might also pack against each other in the same
way as in MC159. However, it cannot rule out the
possibility that two DEDs, in some circumstances,
might get apart and the hydrophobic patch in
DED1 could be exposed to play a role in the
interaction with their binding partners.
RxDL sequence motif in the beginning of helix
6 is highly conserved among proteins containing
a DED or tandem DEDs.
48 Mutation on the motif
in Fadd DED abolished its self-association which
is essential for its apoptosis signaling activity,
49
and this motif is essential also for the antia-
poptotic activity of v-FLIP MC159.
50 The crystalFLIP as an Anti-Cancer Therapeutic Target
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structure of v-FLIP MC159 revealed that the
arginine residue in the RxDL motif interacts with
two acidic residues; an aspartate in the motif and
a glutamate in helix 2 (Fig. 4). The three charged
residues from helix 2 and 6 are highly conserved
among DED proteins, and the sequence motif
characteristic of DED was rephrased into E/D-
RxDL motif. The triad of these three charged
residues seems to play a structural role to hold the
helix 2 and 6 together in correct positions, and
consequently to help stabilize the entire DED fold.
The functional defect of the mutants on this motif
reported previously is more likely a secondary
effect caused by the structural disturbance. This
idea is supported by recent study on Fadd DED.
Even though Fadd R72A mutant (corresponding
to R in E/D-RxDL motif) shows the same circular
dichroism spectra as the wild type, its NMR peaks
exchange broaden and none of the DED
resonances are visible.
51 It implies that the Fadd
R72A mutant has the same helical content as the
wild type but its structural integrity of DED fold
is disturbed to some extent. Therefore, E/D-RxDL
motif conserved in DEDs must play a structural
role to help maintain the stability of DED fold.
TARGETING FLIP FOR CANCER THERAPY
Elevated expression of c-FLIP has been found in
various types of tumor cells which are often
resistant to death-receptor-mediated apoptosis.












71 bladder urothelial carcinoma,
72
and prostate carcinoma.
73 The expression of
c-FLIP has been proven to be one of the major
determinants of the resistance to death ligands
such as FasL and TRAIL, and numerous reports
have shown that down-regulation of c-FLIP
results in sensitizing a various types of resistant
tumor cells.
52,57,60,62,63,66,69,70,74-76 Conversely, forced
expression of c-FLIP renders cells resistant to Fas
and/or TRAIL. These observations collectively
imply that c-FLIP may be an attractive therapeutic
target against at least the above mentioned kinds
of tumors of which malignancy and resistance
Fig. 4. Conserved E/D-RxDL motif in DED fold. Fig. 3. Structure of v-FLIP and comparison of DED-DED
interface with CARD-CARD interface. (A) Structure of
v-FLIP MC159 and the intramolecular DED-DED
interaction. (B) CARD-CARD interaction observed between
Apaf-1 and procaspase-9. (C) Hydrophobic residues in
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have been shown to be strongly dependent upon
c-FLIP overexpression. In addition, v-FLIP K13 of
human herpesvirus 8 (HHV8, also called Kaposi’s
sarcoma-associated herpesvirus, KSHV) has also
been shown to act as a tumor progression factor
by inhibiting receptor-mediated apoptosis.
77
To date, several kinds of small molecules have
been known to lower c-FLIP expression and to
sensitize the resistant tumor cell to death-receptor-
mediated apoptosis.
9 They include DNA-damaging
agents (cisplatin and doxorubicin), RNA synthesis
inhibitor (actinomycin D), protein synthesis inhi-
bitor (cycloheximide), topoisomerase I inhibitors
(camptothecin, 9-NC, topotecan), and histone
deacetylase inhibitors (Trichostatin A).
9 In addi-
tion, the inhibitors of several kinases (MEK1/ 2,
PKC and PI3K) also lower FLIP expression
through blocking the corresponding signaling
pathways for the transcriptional activation of
FLIP. If it is considered that the above-mentioned
tumors depend upon FLIP overexpression for the
resistance to TRAIL,
18,78,79 then the combination of
TRAIL with these agents might be an attractive
therapeutic strategy to kill those tumor cells.
However, it should be noted that the agents
directly targeting FLIP at mRNA or protein levels
has not yet been developed.
8
Antiapoptotic proteins overexpressed in tumor
cells have been recognized as attractive targets for
anti-cancer therapeutic intervention. Compounds
targeted to Bcl-2, IAP, and MDM2 at either
mRNA or protein levels have been developed and
are now in the stages of preclinical and early clinical
trials.
6,8,80 Various antisense oligonucleotides are
targeted to their mRNA’s and small molecule
inhibitors are designed to bind those proteins. The
small molecule inhibitors are designed primarily
based on their crystal structure in complex with
their corresponding proapoptotic proteins; Bcl-XL
complexed with Bad,
81 XIAP complexed with
Smac,
82,83 and MDM2 complexed with p53.
84 In
development of the inhibitors of antiapoptotic
proteins, FLIP seems to be left behind in com-
parison to Bcl-2, IAP and MDM2. It is probably
because FLIP was recognized more recently and
the detailed information on its structure, especially
in complex with Fadd, has not been available.
With regard to FLIP structure, it is notable that
the crystal structure of v-FLIP MC159 has recently
been reported for the first time as an atomic-detail
three-dimensional structure of FLIP.
28,44 The
antisense oligonucleotides and small molecule
inhibitors directly targeting FLIP at the levels of
mRNA and protein are expected to be developed
in near future and tested for the potential as a
new class of anti-cancer drugs.
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